INTENSIFICATION WITH INSULIN GLARGINE 300 U/ML (Gla-300) OR FIRST- GENERATION BASAL INSULINS (BIs) IN PEOPLE WITH TYPE 2 DIABETES (T2D) ON ONCE-WEEKLY GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAs): DELIVER NEW-G

被引：0
|
作者：
Umpierrez, G. [1 ]
Bailey, T. [2 ]
Mahieu, A. [3 ]
Li, X. [4 ]
Mabunay, M. A. [5 ]
Fonseca, V [6 ]
机构：
[1] Emory Univ, Sch Med, Atlanta, GA USA
[2] AMCR Inst, Escondido, CA USA
[3] Sanofi, Paris, France
[4] Sanofi, Bridgewater, NJ USA
[5] Sanofi, Singapore, Singapore
[6] Tulane Univ, Med Ctr, New Orleans, LA USA
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE139
引用
收藏
页码：S83 / S83
页数：1
相关论文
共 50 条
  • [41] Efficacy and safety of once-weekly glucagon-like peptide-1 receptor agonists compared with exenatide and liraglutide in type 2 diabetes: a systemic review of randomised controlled trials
    Xue, X.
    Ren, Z.
    Zhang, A.
    Yang, Q.
    Zhang, W.
    Liu, F.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2016, 70 (08) : 649 - 656
  • [42] Efficacy and safety of once-weekly insulin icodec vs once-daily basal insulin in type 2 diabetes according to baseline glucagon-like peptide-1 receptor agonist use: ONWARDS 1-5
    Vilsboll, T.
    Bangsgaard, K. O.
    Fu, A.
    Kellerer, M.
    Sogaard, S. B.
    Goldenberg, R.
    DIABETOLOGIA, 2024, 67 : S9 - S9
  • [43] Real-World Persistence, Adherence, Health Care Resource Utilization (HRU), and Hypoglycemia in People with Type 2 Diabetes (T2D) Continuing the 2nd-Generation (2nd-Gen) Basal Insulin (BI) ( Glargine 300 U/mL [Gla-300]) vs. Switching to a 1st-Generation (1st-Gen) BI (Glargine 100 U/mL [Gla-100] or Detemir [IDet 100 U/mL])
    Edelman, Steven
    Goldman, Jennifer D.
    Malone, Daniel C.
    Preblick, Ron
    Munaga, Kovida
    Li, Xuan
    Gill, Jasvinder
    Gangi, Sumana
    DIABETES, 2022, 71
  • [44] Effectiveness and Safety of Insulin Glargine 300 U/mL (Gla-300) in Insulin-Naive People with Type 2 Diabetes (T2DM): ATOS Study Subgroup Analysis by Baseline (BL) HbA1c
    Khan, Niaz
    Tirosh, Amir
    Vargas-Uricoechea, Hernando
    Mabunay, Maria Aileen N.
    Coudert, Mathieu
    Pilorget, Valerie
    Galstyan, Gagik R.
    DIABETES, 2021, 70
  • [45] Comparative effectiveness of once-weekly glucagon-like peptide-1 receptor agonists with regard to 6-month glycaemic control and weight outcomes in patients with type 2 diabetes
    Unni, Sudhir
    Wittbrodt, Eric
    Ma, Junjie
    Schauerhamer, Marisa
    Hurd, Jeff
    Ruiz-Negron, Natalia
    McAdam-Marx, Carrie
    DIABETES OBESITY & METABOLISM, 2018, 20 (02): : 468 - 473
  • [46] Efficacy and safety of once-weekly dulaglutide, a glucagon-like peptide (GLP)-1 receptor agonist (RA), in three insulin-related clinical settings in Type 2 diabetes
    Rachman, J.
    Lebrec, J.
    Gentilella, R.
    Milicevic, Z.
    DIABETIC MEDICINE, 2018, 35 : 81 - 81
  • [47] A post-hoc pooled analysis to evaluate efficacy and safety of insulin glargine 300 U/mL in insulin-naïve people with type 2 diabetes with/ without prior use of glucagon-like peptide-1 receptor agonist therapy
    Cheng, Alice Y. Y.
    Mauricio, Didac
    Ritzel, Robert
    Al-Sofiani, Mohammed E.
    Bailey, Timothy
    Mabunay, Maria Aileen
    Bonnemaire, Mireille
    Melas-Melt, Lydie
    Mimouni, Safia
    Davies, Melanie
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2024, 217
  • [48] Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA)-Experienced Adults with Type 2 Diabetes (T2D) Switching to Once-Weekly (OW) Semaglutide in a Real-World Setting-SURE Program Post Hoc Analysis
    Rudofsky, Gottfried
    Menzen, Markus
    Potier, Louis
    Catarig, Andrei-Mircea
    Clark, Alice
    Priyadarshini, Prachi
    Abreu, Cristina
    DIABETES, 2023, 72
  • [49] Glycemic Outcomes and Persistence with Basal Insulin and Glucagon-Like Peptide-1 Receptor Agonists among Patients with T2D: Simultaneous vs. Sequential Initiation
    Peng, Xuejun V.
    Ayyagari, Rajeev
    Lubwama, Robert
    Van Vleet, Melvin J.
    Shi, Lizheng
    Price-Haywood, Eboni G.
    Hollander, Priscilla
    Fonseca, Vivian
    DIABETES, 2019, 68
  • [50] Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9)
    Pozzilli, Paolo
    Norwood, Paul
    Jodar, Esteban
    Davies, Melanie J.
    Ivanyi, Tibor
    Jiang, Honghua
    Woodward, D. Bradley
    Milicevic, Zvonko
    DIABETES OBESITY & METABOLISM, 2017, 19 (07): : 1024 - 1031
12345